---
title: "Adaptive Biotechnologies Corporation (ADPT.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/ADPT.US.md"
symbol: "ADPT.US"
name: "Adaptive Biotechnologies Corporation"
industry: "Life Sciences Tools and Services"
---

# Adaptive Biotechnologies Corporation (ADPT.US)

| Item | Detail |
|------|--------|
| Industry | Life Sciences Tools and Services |
| Location | US Market |
| Website | [www.adaptivebiotech.com](https://www.adaptivebiotech.com) |

## Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to gen...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:13.000Z

**Overall: C (0.48)**

**Industry**: Life Sciences Tools and Services

| Metric | Value |
|--------|-------|
| Industry Ranking | 27 / 62 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 54.77% |  |
| Net Profit YoY | 62.69% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 11.28 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 2.47B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 276.98M |  |


**Multi Score**: C

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -28.23% | E |
| Profit Margin | -21.48% | D |
| Gross Margin | 40.38% | B |

#### Growth Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 54.77% | A |
| Net Profit YoY | 62.69% | B |
| Total Assets YoY | -4.94% | D |
| Net Assets YoY | 11.12% | B |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -465.51% | E |
| OCF YoY | 54.77% | A |

#### Operating Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.53 | C |

#### Debt Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 56.12% | D |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Adaptive Biotechnologies Corporation",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-28.23%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-21.48%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "40.38%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "A",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "54.77%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "62.69%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-4.94%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "11.12%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-465.51%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "54.77%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "C",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.53",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "D",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "56.12%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | ChromaDex (US.CDXC) | A | A | A | B | B | A |
| 02 | Agilent Tech (US.A) | A | C | B | C | C | B |
| 03 | Waters (US.WAT) | A | B | B | C | C | B |
| 04 | WuXi Biologics (US.WXXWY) | B | B | D | A | B | B |
| 05 | West Pharmaceutical (US.WST) | B | B | B | B | C | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -41.48 | 52/59 | - | - | - |
| PB | 11.28 | 49/59 | 12.51 | 10.63 | 7.03 |
| PS (TTM) | 8.91 | 47/59 | 10.55 | 9.08 | 7.09 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-17T05:00:00.000Z

Total Analysts: **8**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 5 | 63% |
| Overweight | 2 | 25% |
| Hold | 1 | 13% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 15.25 |
| Highest Target | 21.00 |
| Lowest Target | 18.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/ADPT.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/ADPT.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/ADPT.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.